» Articles » PMID: 31425693

Prevalence, Risk Factors, and Surveillance Patterns for Gastric Intestinal Metaplasia Among Patients Undergoing Upper Endoscopy with Biopsy

Overview
Date 2019 Aug 20
PMID 31425693
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Gastric intestinal metaplasia (GIM) is an important precursor lesion to gastric cancer (GC), the second leading cause of cancer death worldwide. There exist few data regarding the prevalence of, risk factors for, and clinical practice patterns regarding GIM in the United States. Furthermore, there are currently no U.S. guidelines regarding screening/surveillance for GIM.

Methods: All consecutive upper endoscopic procedures from 2 academic medical centers in Seattle between 1999 and 2014 were reviewed. Demographic, clinical, and endoscopic covariates were recorded at time of endoscopy. Procedures with gastric biopsy were matched to final the histologic diagnoses, including the presence of Helicobacter pylori. Cases of GIM and dysplasia were recorded and compared with non-GIM controls using univariate and multivariable regression. Surveillance patterns for cases of GIM were recorded.

Results: Data from 36,799 upper endoscopies, 17,710 gastric biopsies, 2073 cases of GIM, 43 cases of dysplasia, and 78 cases of GC were captured. The point prevalence of GIM was 11.7% in patients who underwent gastric biopsy. Non-white race (P < .001), increasing age (P < .001), and presence of H pylori (P < .001) were associated with GIM. If GIM was present, increasing age (P < .001) and male gender (P < .001) were associated with progression, and the presence of H pylori (P < .001) was inversely associated with progression to dysplasia/GC. Few cases of GIM/dysplasia/GC were identified during procedures for GIM screening/surveillance. Only 16% of patients with a diagnosis of GIM received a recommendation for surveillance.

Conclusions: There is a high prevalence of GIM among non-white and Hispanic Americans. Risk factors for development of GIM may be distinct from the risk factors for progression to GC.

Citing Articles

Global prevalence of gastric intestinal metaplasia: a systematic review and meta-analysis.

Soroorikia S, Kazeminia M, Qaderi K, Ziapour A, Hodhodi T, Javanbakht Z Syst Rev. 2024; 13(1):247.

PMID: 39342409 PMC: 11439247. DOI: 10.1186/s13643-024-02633-x.


Endoscopic Surveillance of Gastric Intestinal Metaplasia: A Retrospective Cohort Study.

Yoon J, Katcher E, Cohen E, Ward S, Rouphael C, Itzkowitz S J Clin Gastroenterol. 2024; .

PMID: 39042489 PMC: 11739429. DOI: 10.1097/MCG.0000000000002039.


Association between country of birth and gastric intestinal metaplasia: a retrospective cohort study.

Haghighat S, Blandon C, Goldberg D, Kumar S Lancet Reg Health Am. 2023; 28:100635.

PMID: 38090256 PMC: 10711156. DOI: 10.1016/j.lana.2023.100635.


Cancer Progress and Priorities: Gastric Cancer.

Alagesan P, Goodwin J, Garman K, Epplein M Cancer Epidemiol Biomarkers Prev. 2023; 32(4):473-486.

PMID: 37009691 PMC: 10071414. DOI: 10.1158/1055-9965.EPI-22-0994.


The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress?.

Jardim S, de Souza L, de Souza H Int J Environ Res Public Health. 2023; 20(4).

PMID: 36834334 PMC: 9962127. DOI: 10.3390/ijerph20043640.